glp 1 cardiovascular benefit The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management | Current Risk Reports The conversation around GLP-1 medications
Description
Unpublished results from the first phase II trial with the triple combination of semaglutide, cilofexor and/or firsocostat treatment for 24 weeks in 108 patients with NASH showed significant improvements in hepatic steatosis (measured with MRI) and liver injury (measured by serum alanine aminotransferase) in the combination treatment arm vs semaglutide monotherapy (56)
The SELECT trial , published in the New England Journal of Medicine and conducted across 804 sites in 41 countries with 17,604 participants, showed semaglutide reduced major adverse cardiovascular events by 20% in people with obesity but without diabetes
They do not contain GLP-1 receptor agonists and will not produce the same effects as Ozempic or Wegovy (6)
The five-level model: a new approach to organizing body-composition research
Creating end-to-end health programs for GLP-1 users: GLP-1 therapy creates needs beyond medication, prompting demand for integrated health frameworks
While the Wegovy pill has name-brand cred to lean on, Foundayo has fewer dietary restrictions
